These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Quantitative susceptibility mapping based hybrid feature extraction for diagnosis of Parkinson's disease. Xiao B; He N; Wang Q; Cheng Z; Jiao Y; Haacke EM; Yan F; Shi F Neuroimage Clin; 2019; 24():102070. PubMed ID: 31734535 [TBL] [Abstract][Full Text] [Related]
23. A prospective multi-centre study of susceptibility map-weighted MRI for the diagnosis of neurodegenerative parkinsonism. Sung YH; Kim JS; Yoo SW; Shin NY; Nam Y; Ahn TB; Yoo D; Lee KM; Kim HG; Koh SB; Kim J; Kim I; Kwon DY; Lee Y; Kim C; Chung SJ; Jo S; Lee SH; Kim SJ; Kim M; Lyoo CH; Baek MS; Kang SY; Chang SK; Jo SW; Lee SA; Ma HI; Kim YE; Kim ES; Kim YJ; Kim HS; Woo MH; Choi HJ; Kim EY Eur Radiol; 2022 May; 32(5):3597-3608. PubMed ID: 35064313 [TBL] [Abstract][Full Text] [Related]
24. Seed point discontinuity-based segmentation method for the substantia nigra and the red nucleus in quantitative susceptibility maps. Guo T; Song Y; Li J; Fan M; Yan X; He A; Huang D; Shen C; Zhang G; Yang G J Magn Reson Imaging; 2018 Oct; 48(4):1112-1119. PubMed ID: 29603826 [TBL] [Abstract][Full Text] [Related]
25. Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2. Barbosa JH; Santos AC; Tumas V; Liu M; Zheng W; Haacke EM; Salmon CE Magn Reson Imaging; 2015 Jun; 33(5):559-65. PubMed ID: 25721997 [TBL] [Abstract][Full Text] [Related]
26. Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients. Du G; Lewis MM; Sica C; He L; Connor JR; Kong L; Mailman RB; Huang X Mov Disord; 2018 Sep; 33(9):1423-1431. PubMed ID: 29756399 [TBL] [Abstract][Full Text] [Related]
28. Differential Effect of Iron and Myelin on Susceptibility MRI in the Substantia Nigra. Lee H; Cho H; Lee MJ; Kim TH; Roh J; Lee JH Radiology; 2021 Dec; 301(3):682-691. PubMed ID: 34609198 [TBL] [Abstract][Full Text] [Related]
29. Comparison of susceptibility-weighted imaging and susceptibility map-weighted imaging for the diagnosis of Parkinsonism with nigral hyperintensity. Bae YJ; Song YS; Choi BS; Kim JM; Nam Y; Kim JH Eur J Radiol; 2021 Jan; 134():109398. PubMed ID: 33264728 [TBL] [Abstract][Full Text] [Related]
30. Radiomic Features of the Nigrosome-1 Region of the Substantia Nigra: Using Quantitative Susceptibility Mapping to Assist the Diagnosis of Idiopathic Parkinson's Disease. Cheng Z; Zhang J; He N; Li Y; Wen Y; Xu H; Tang R; Jin Z; Haacke EM; Yan F; Qian D Front Aging Neurosci; 2019; 11():167. PubMed ID: 31379555 [No Abstract] [Full Text] [Related]
31. Susceptibility map-weighted imaging (SMWI) for neuroimaging. Gho SM; Liu C; Li W; Jang U; Kim EY; Hwang D; Kim DH Magn Reson Med; 2014 Aug; 72(2):337-46. PubMed ID: 24006248 [TBL] [Abstract][Full Text] [Related]
32. High-resolution QSM for functional and structural depiction of subthalamic nuclei in DBS presurgical mapping. Dimov AV; Gupta A; Kopell BH; Wang Y J Neurosurg; 2019 Aug; 131(2):360-367. PubMed ID: 30095333 [TBL] [Abstract][Full Text] [Related]
33. Swallow tail sign on susceptibility map-weighted imaging (SMWI) for disease diagnosing and severity evaluating in parkinsonism. Liu X; Wang N; Chen C; Wu PY; Piao S; Geng D; Li Y Acta Radiol; 2021 Feb; 62(2):234-242. PubMed ID: 32380911 [TBL] [Abstract][Full Text] [Related]
34. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease. Lehéricy S; Bardinet E; Poupon C; Vidailhet M; François C Mov Disord; 2014 Nov; 29(13):1574-81. PubMed ID: 25308960 [TBL] [Abstract][Full Text] [Related]
35. Nigrosome 1 imaging: technical considerations and clinical applications. Kim EY; Sung YH; Lee J Br J Radiol; 2019 Sep; 92(1101):20180842. PubMed ID: 31067082 [TBL] [Abstract][Full Text] [Related]
36. [A multi-channel input convolutional neural network for artifact reduction in quantitative susceptibility mapping]. Si W; Feng Y Nan Fang Yi Ke Da Xue Xue Bao; 2022 Dec; 42(12):1799-1806. PubMed ID: 36651247 [TBL] [Abstract][Full Text] [Related]
37. Nigrosome 1 visibility and its association with nigrostriatal dopaminergic loss in Parkinson's disease. Kim HK; Kim T; Baek MS; Kim EY; Sung YH; Lee JH; Ryu YH; Ahn SJ; Yoo HS; Lyoo CH Eur J Neurol; 2023 Jun; 30(6):1639-1647. PubMed ID: 36915220 [TBL] [Abstract][Full Text] [Related]
38. STrategically Acquired Gradient Echo (STAGE) imaging, part I: Creating enhanced T1 contrast and standardized susceptibility weighted imaging and quantitative susceptibility mapping. Chen Y; Liu S; Wang Y; Kang Y; Haacke EM Magn Reson Imaging; 2018 Feb; 46():130-139. PubMed ID: 29056394 [TBL] [Abstract][Full Text] [Related]
39. Visualization of Nigrosome 1 from the Viewpoint of Anatomic Structure. Arai N; Kan H; Ogawa M; Uchida Y; Takizawa M; Omori K; Miyati T; Kasai H; Kunitomo H; Shibamoto Y AJNR Am J Neuroradiol; 2020 Jan; 41(1):86-91. PubMed ID: 31806600 [TBL] [Abstract][Full Text] [Related]
40. Multimodal assessment of nigrosomal degeneration in Parkinson's disease. Langley J; Huddleston DE; Crosson B; Song DD; Factor SA; Hu X Parkinsonism Relat Disord; 2020 Nov; 80():102-107. PubMed ID: 32979784 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]